Key Highlights

  • Phase 2 data on neoadjuvant BOT/BAL combination due October 25 at ESMO.
  • Study, called NEOASIS, targets MMR-deficient, MSI-high colorectal cancer patients.
  • Prior data showed a 90% pathological response rate in that cohort.
  • Agenus shares trade near $5.01, with a market value of about $208.6 million.

Agenus Inc. (NASDAQ: AGEN) is scheduled to present Phase 2 results from its NEOASIS study of neoadjuvant BOT/BAL in MMR-deficient colorectal cancer at the ESMO 2026 congress on October 25.

What Happened

The NEOASIS study is evaluating the neoadjuvant BOT/BAL combination in patients with mismatch repair deficient (dMMR), microsatellite instability-high (MSI-H) colorectal cancer.

Phase 2 results noted April 29, 2025 reported a pathological response rate of 90% in the dMMR/MSI-H cohort.

Market Reaction

Agenus, a small-cap company with a market value of approximately $208.6 million, traded near $5.01 per share, up $0.01, or 0.2%, according to the disclosed pipeline database.

Outlook

Phase 2 results from the NEOASIS study are scheduled to be shared at ESMO on October 25, 2026.

What is Agenus studying in the NEOASIS trial?

Agenus is studying a neoadjuvant BOT/BAL combination in patients with MMR-deficient, MSI-high colorectal cancer.

What has NEOASIS data shown so far?

Data noted April 29, 2025 reported a 90% pathological response rate in the dMMR/MSI-H cohort.

When will Agenus present the full Phase 2 results?

Phase 2 results are scheduled to be shared at the ESMO 2026 congress on October 25.